Estudo randomizado | Adição de elotuzumabe à lenalidomida e à dexametasona para pacientes com mieloma múltiplo recém-diagnosticado e inelegível a transplante.

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial – The Lancet Haematology (link para o resumo – $ para o texto completo)

Comentário: Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma – Cancer Therapy Adviser

Comentário no Twitter

NEW research— Addition of elotuzumab to lenalidomide and dexamethasone did not improve progression-free survival in patients w/ newly diagnosed, transplantation ineligible multiple myeloma: results of the ph3 ELOQUENT-1 trial #mmsm https://t.co/8O3O6ikCJO pic.twitter.com/qe5V7Om9DN

— The Lancet Haematology (@TheLancetHaem) May 12, 2022